NL193066C - Methyl,isopropyl-4-(2,1,3-benzoxadiazool-4-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylaat en farmaceutisch preparaat dat deze verbinding bevat. - Google Patents
Methyl,isopropyl-4-(2,1,3-benzoxadiazool-4-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylaat en farmaceutisch preparaat dat deze verbinding bevat. Download PDFInfo
- Publication number
- NL193066C NL193066C NL7909024A NL7909024A NL193066C NL 193066 C NL193066 C NL 193066C NL 7909024 A NL7909024 A NL 7909024A NL 7909024 A NL7909024 A NL 7909024A NL 193066 C NL193066 C NL 193066C
- Authority
- NL
- Netherlands
- Prior art keywords
- compound
- formula
- benzoxadiazol
- isopropyl
- dimethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- -1 2,1,3-benzoxadiazol-4-yl Chemical group 0.000 title description 4
- JNLUMMRKXUTNAA-UHFFFAOYSA-N 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-5-propan-2-yloxycarbonyl-1,4-dihydropyridine-3-carboxylic acid Chemical compound CC(C)OC(=O)C1=C(C)NC(C)=C(C(O)=O)C1C1=CC=CC2=NON=C12 JNLUMMRKXUTNAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 8
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical group C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002213 calciumantagonistic effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UKVYVZLTGQVOPX-IHWYPQMZSA-N (z)-3-aminobut-2-enoic acid Chemical compound C\C(N)=C\C(O)=O UKVYVZLTGQVOPX-IHWYPQMZSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical class C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical class C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- COLPLFZHPXIFCQ-UHFFFAOYSA-N 1,4-dihydropyridine-3,5-dicarboxylic acid Chemical class OC(=O)C1=CNC=C(C(O)=O)C1 COLPLFZHPXIFCQ-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010058842 Cerebrovascular insufficiency Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- DYYYPIJLRRHUPR-UHFFFAOYSA-N dimethyl 1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=CNC=C(C(=O)OC)C1 DYYYPIJLRRHUPR-UHFFFAOYSA-N 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1283578A CH639659A5 (de) | 1978-12-18 | 1978-12-18 | Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung. |
| CH1283578 | 1978-12-18 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL7909024A NL7909024A (nl) | 1980-06-20 |
| NL193066B NL193066B (nl) | 1998-05-06 |
| NL193066C true NL193066C (nl) | 1998-09-08 |
Family
ID=4386824
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7909024A NL193066C (nl) | 1978-12-18 | 1979-12-14 | Methyl,isopropyl-4-(2,1,3-benzoxadiazool-4-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylaat en farmaceutisch preparaat dat deze verbinding bevat. |
| NL990014C NL990014I1 (nl) | 1978-12-18 | 1999-05-11 | Methyl, isopropyl-4-(2,1,3-benzoxadiazool-4-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylaat en farmaceutisch preparaat dat deze verbinding bevat. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL990014C NL990014I1 (nl) | 1978-12-18 | 1999-05-11 | Methyl, isopropyl-4-(2,1,3-benzoxadiazool-4-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylaat en farmaceutisch preparaat dat deze verbinding bevat. |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS5583783A (sv) |
| AU (1) | AU536055B2 (sv) |
| BE (1) | BE880591A (sv) |
| CH (1) | CH639659A5 (sv) |
| CY (1) | CY1321A (sv) |
| DE (1) | DE2949491A1 (sv) |
| FR (1) | FR2444681A1 (sv) |
| GB (2) | GB2103203B (sv) |
| HK (1) | HK16086A (sv) |
| IE (1) | IE49496B1 (sv) |
| IT (1) | IT1164097B (sv) |
| KE (1) | KE3593A (sv) |
| MY (1) | MY8500130A (sv) |
| NL (2) | NL193066C (sv) |
| NZ (1) | NZ192422A (sv) |
| SE (1) | SE445219B (sv) |
| SG (1) | SG97585G (sv) |
| ZA (1) | ZA796842B (sv) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3022030A1 (de) * | 1980-06-12 | 1981-12-17 | Bayer Ag, 5090 Leverkusen | 4-thiazol- bzw. 4-imidazol-substituierte, 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel |
| CH655658B (sv) * | 1980-09-18 | 1986-05-15 | ||
| EP0080220B1 (en) * | 1981-11-17 | 1986-02-19 | FISONS plc | Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals |
| ZA83959B (en) * | 1982-03-10 | 1984-09-26 | Sandoz Ltd | 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them |
| US4414213A (en) * | 1982-03-22 | 1983-11-08 | Mead Johnson & Company | Dihydropyridyl cyclic imidate esters and their pharmaceutical use |
| FR2528431B1 (fr) * | 1982-06-15 | 1986-01-10 | Sandoz Sa | Nouveaux derives de la 1,4-dihydropyridine, leur preparation et leur utilisation comme medicaments |
| IL68975A (en) * | 1982-06-15 | 1987-01-30 | Sandoz Ag | 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydropyridine-3,5-dicarboxylic acid ester derivatives in optically active form,their preparation and pharmaceutical compositions containing them |
| JPS5978186A (ja) * | 1982-10-27 | 1984-05-04 | Yoshitomi Pharmaceut Ind Ltd | １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体 |
| US4794111A (en) * | 1984-05-23 | 1988-12-27 | Bayer Aktiengesellschaft | Dihydropyridine preparations containing β-blockers |
| HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
| US5260321A (en) * | 1984-11-12 | 1993-11-09 | Sandoz Ltd. | Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins |
| HU197201B (en) * | 1985-10-01 | 1989-03-28 | Sandoz Ag | Process for producing oral pharmaceutical compositions of controlled solubility of the active components |
| DE3542794A1 (de) * | 1985-12-04 | 1987-06-11 | Bayer Ag | Antihypertensives kombinationspraeparat |
| GB8626217D0 (en) * | 1986-11-03 | 1986-12-03 | Sandoz Ltd | Pharmaceutical compositions |
| US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
| KR940003492B1 (ko) * | 1988-10-27 | 1994-04-23 | 주식회사 유한양행 | 1,4-디하이드로피리딘유도체 및 그의 제조방법 |
| DE4222770A1 (de) * | 1992-07-10 | 1994-01-13 | Bayer Ag | Lichtaktivierbare 1-(2-Nitrobenzyl)-substituierte 1,4-Dihydropyridine |
| IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
| WO2005023787A1 (en) * | 2003-09-10 | 2005-03-17 | Shasun Chemicals And Drugs Limited | Process for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde |
| CN103613584B (zh) * | 2013-11-27 | 2016-04-27 | 沈阳药科大学 | 一种伊拉地平合成产物后处理的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670824C3 (de) * | 1967-03-20 | 1978-08-03 | Bayer Ag, 5090 Leverkusen | 1,4-Dihydropyridin-33-dicarbonsäurealkylester |
| FR2320750A1 (fr) * | 1975-08-12 | 1977-03-11 | Hexachimie | Dihydro-1,4 pyridines et leur application therapeutique |
| DE2616991A1 (de) * | 1976-04-17 | 1977-10-27 | Bayer Ag | Heterocyclisch-substituierte schwefelhaltige dihydropyridine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| JPS5373327A (en) * | 1976-12-13 | 1978-06-29 | Matsushita Electric Ind Co Ltd | Power source system |
| DK149855C (da) * | 1977-06-20 | 1987-04-21 | Sandoz Ag | Analogifremgangsmaade til fremstilling af 1,4-dihydropyridinderivater |
-
1978
- 1978-12-18 CH CH1283578A patent/CH639659A5/de not_active IP Right Cessation
-
1979
- 1979-12-08 DE DE19792949491 patent/DE2949491A1/de active Granted
- 1979-12-11 SE SE7910188A patent/SE445219B/sv not_active IP Right Cessation
- 1979-12-13 BE BE1/9643A patent/BE880591A/fr not_active IP Right Cessation
- 1979-12-14 IT IT51095/79A patent/IT1164097B/it active Protection Beyond IP Right Term
- 1979-12-14 GB GB08215988A patent/GB2103203B/en not_active Expired
- 1979-12-14 NL NL7909024A patent/NL193066C/nl not_active IP Right Cessation
- 1979-12-14 CY CY1321A patent/CY1321A/xx unknown
- 1979-12-14 GB GB7943113A patent/GB2037766B/en not_active Expired
- 1979-12-17 JP JP16396579A patent/JPS5583783A/ja active Granted
- 1979-12-17 AU AU53896/79A patent/AU536055B2/en not_active Expired
- 1979-12-17 IE IE2445/79A patent/IE49496B1/en not_active IP Right Cessation
- 1979-12-17 FR FR7930829A patent/FR2444681A1/fr active Granted
- 1979-12-17 NZ NZ192422A patent/NZ192422A/xx unknown
- 1979-12-18 ZA ZA00796842A patent/ZA796842B/xx unknown
-
1985
- 1985-12-20 SG SG975/85A patent/SG97585G/en unknown
- 1985-12-30 MY MY130/85A patent/MY8500130A/xx unknown
-
1986
- 1986-01-08 KE KE3593A patent/KE3593A/xx unknown
- 1986-03-06 HK HK160/86A patent/HK16086A/xx not_active IP Right Cessation
-
1999
- 1999-05-11 NL NL990014C patent/NL990014I1/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE49496B1 (en) | 1985-10-16 |
| AU5389679A (en) | 1980-06-26 |
| IT7951095A0 (it) | 1979-12-14 |
| GB2103203A (en) | 1983-02-16 |
| IT1164097B (it) | 1987-04-08 |
| GB2037766A (en) | 1980-07-16 |
| JPS5583783A (en) | 1980-06-24 |
| CH639659A5 (de) | 1983-11-30 |
| SG97585G (en) | 1986-07-18 |
| NZ192422A (en) | 1982-09-14 |
| ZA796842B (en) | 1981-07-29 |
| DE2949491A1 (de) | 1980-06-26 |
| FR2444681B1 (sv) | 1982-10-29 |
| NL7909024A (nl) | 1980-06-20 |
| SE445219B (sv) | 1986-06-09 |
| BE880591A (fr) | 1980-06-13 |
| DE2949491C2 (sv) | 1988-10-27 |
| CY1321A (en) | 1986-06-27 |
| GB2103203B (en) | 1983-06-08 |
| GB2037766B (en) | 1983-02-16 |
| SE7910188L (sv) | 1980-06-19 |
| KE3593A (en) | 1986-02-07 |
| NL193066B (nl) | 1998-05-06 |
| FR2444681A1 (fr) | 1980-07-18 |
| NL990014I1 (nl) | 1999-07-01 |
| JPH0369910B2 (sv) | 1991-11-05 |
| HK16086A (en) | 1986-03-14 |
| MY8500130A (en) | 1985-12-31 |
| AU536055B2 (en) | 1984-04-19 |
| IE792445L (en) | 1980-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL193066C (nl) | Methyl,isopropyl-4-(2,1,3-benzoxadiazool-4-yl)-2,6-dimethyl-1,4-dihydro pyridine-3,5-dicarboxylaat en farmaceutisch preparaat dat deze verbinding bevat. | |
| US4466972A (en) | Benzoxadiazoles and benzothiadiazoles, their preparation and pharmaceutical compositions containing them | |
| CA1205480A (en) | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them | |
| US4220649A (en) | 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives | |
| US5654309A (en) | Pyridopyrimidine derivatives, their production and use | |
| EP0000150B1 (en) | Dihydropyridine derivatives, process for their production and pharmaceutical compositions containing them. | |
| EP0097821B1 (en) | Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them | |
| JP3012352B2 (ja) | 薬剤としてのｎ−アルキル化１，４−ジヒドロピリジンジカルボン酸エステル類の使用、新規化合物およびそれらの製造方法 | |
| GB2041358A (en) | Benzoxadiazoles and benzothiadiazoles | |
| GB2139212A (en) | Dihydropyridyl cyclic imidate esters | |
| EP1470108B1 (en) | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | |
| NO139130B (no) | Fremgangsmaate til fremstilling av 2-alkylamino-dihydropyridiner | |
| US4061637A (en) | Certain 4-aryl-5-(4-phenylpiperazino)alkyl-4-thiazolin-2-ones | |
| SK12498A3 (en) | Thalidomide analogues from the piperidine-2,6-dione class | |
| JPS6289662A (ja) | １，４−ジヒドロピリジン誘導体 | |
| US3920823A (en) | Use of unsymmetrical esters of n-substituted 1,4-dihydropyridine 3,5-dicarboxylic acid as cardio-vascular agents | |
| US4491581A (en) | 4-(2,1,3-Benzoxadiazol-4-yl)-1,4-dihydropyridazine derivatives, their production and pharmaceutical compositions | |
| US4567271A (en) | Benzoxadiazoles and benzothiadiazoles | |
| ATE66677T1 (de) | Isomere von derivaten der dihydropyridin-3,5dicarboxyls|ureester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| NL8105035A (nl) | 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-pyridinederivaten, werkwijzen voor hun bereiding en van farmaceutische preparaten die ze bevatten. | |
| US4136187A (en) | Antihypertensive 2-amino-4,5-dihydropyridine derivatives | |
| JP2006503042A (ja) | カルシウムチャンネル遮断薬 | |
| US4277483A (en) | 1.4-Dihydropyridine-derivatives with antihypertensive activity | |
| EP0216542B1 (en) | Dihydropyridine derivatives | |
| US20040006110A1 (en) | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| CNR | Transfer of rights (patent application after its laying open for public inspection) |
Free format text: NOVARTIS AG |
|
| AC1 | Application for a supplementary protection certificate |
Free format text: 990014, 19990511 |
|
| BC1 | Further communications concerning applications for a supplementary protection certificate |
Free format text: 990014 |
|
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Free format text: 19991214 |